ZCM
PBYI icon

Zebra Capital Management’s Puma Biotechnology PBYI Stock Holding History

Zebra Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,058
Closed -$76K – 159
2021
Q4 		$76K Sell
25,058
-9,237
-27% -$40.1K 0.12% 146
2021
Q3 		$240K Buy
34,295
+3,390
+11% +$25.4K 0.29% 125
2021
Q2 		$284K Sell
30,905
-3,338
-10% -$33.8K 0.33% 109
2021
Q1 		$333K Buy
+34,243
New +$382K 0.37% 98

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Zebra Capital Management's PBYI Position: Q1 2022 in Review

Zebra Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2022, closing a stake of 25,058 shares — an estimated $76K sold.

Zebra Capital Management first reported a position in PBYI in Q1 2021 and held it in 4 quarters. The position peaked at $333K in Q1 2021. 104 funds tracked by Wall St. Rank hold PBYI as of Q1 2022.

  • Zebra Capital Management reported no remaining Puma Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Zebra Capital Management sold 25,058 Puma Biotechnology shares in Q1 2022, an estimated $76K.
  • Zebra Capital Management first reported a position in Puma Biotechnology in Q1 2021 and held it in 4 quarters.
  • Zebra Capital Management's Puma Biotechnology position peaked at $333K in Q1 2021.
  • 104 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2022.

Based on Zebra Capital Management's 13F filing for Q1 2022, filed 16 May 2022.